Tag: AC Immune
December 9, 2020
3 Alzheimer’s Disease Treatment Stocks on the NASDAQ
The Alzheimer's disease treatment market is projected to reach US$12.9 billion by 2028. Which stocks should be on investors' radar?
December 12, 2019
Biotech Trends 2019: M&A Slows, CNS Therapies Make Headlines
2019 marked another critical year of growth for the biotech market. Learn about key biotech trends before the new year... November 13, 2018
AC Immune Reports Third Quarter 2018 Financial Results and Corporate Update
AC Immune (NASDAQ:ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, announced financial results for... April 5, 2018
AC Immune Announces the Selection of Tau Small Molecules for Clinical Development in Alzheimer’s disease
AC Immune (NASDAQ:ACIU), a Swiss-based, clinical stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that... March 20, 2018
AC Immune reports full-year 2017 financial results
AC Immune (NASDAQ: ACIU), a Swiss-based, clinical stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced...
October 26, 2017
The State of Novel Alzheimer's Treatments
Alzheimer's already affects nearly five million Americans, with a growing population incoming, the need for an improved treatment is a... September 23, 2016